Childhood-Onset Leber Hereditary Optic Neuropathy-Clinical and Prognostic Insights.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
05 2023
Historique:
received: 14 03 2022
revised: 06 12 2022
accepted: 07 12 2022
medline: 18 4 2023
pubmed: 22 12 2022
entrez: 21 12 2022
Statut: ppublish

Résumé

To investigate the clinical and molecular genetic features of childhood-onset Leber hereditary optic neuropathy (LHON) to gain a better understanding of the factors influencing the visual outcome in this atypical form of the disease. Retrospective cohort study. We retrospectively included 2 cohorts of patients with LHON with onset of visual loss before the age of 12 years from Italy and the United Kingdom. Ophthalmologic evaluation, including best-corrected visual acuity, orthoptic evaluation, slit-lamp biomicroscopy, visual field testing, and optical coherence tomography, was considered. Patients were classified based on both the age of onset and the pattern of visual loss. A total of 68 patients were stratified based on the age of onset of visual loss: group 1 (<3 years): 14 patients (20.6%); group 2 (≥3 to <9 years): 27 patients (39.7%); and group 3 (≥9 to ≤12 years): 27 patients (39.7%). Patients in group 2 achieved a better visual outcome than those in group 3. Patients in groups 1 and 2 had better mean deviation on visual field testing than those in group 3. The mean ganglion cell layer thickness on optical coherence tomography in group 2 was higher than those in groups 1 and 3. Patients were also categorized based on the pattern of visual loss as follows: Subacute Bilateral: 54 patients (66.7%); Insidious Bilateral: 14 patients (17.3%); Unilateral: 9 patients (11.1%); and Subclinical Bilateral: 4 patients (4.9%). Children who lose vision from LHON before the age of 9 years have a better visual prognosis than those who become affected in later years, likely representing a "form frustre" of the disease.

Identifiants

pubmed: 36543315
pii: S0002-9394(22)00501-3
doi: 10.1016/j.ajo.2022.12.014
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

99-107

Subventions

Organisme : Medical Research Council
ID : G0701386
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1002570
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR301696
Pays : United Kingdom
Organisme : Department of Health
ID : BRC-1215-20014
Pays : United Kingdom

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Piero Barboni (P)

From the Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan (P.B., M.L.C., M.B., V.S., F.B.); Department of ophthalmology, Studio Oculistico d'Azeglio (P.B., M.C.). Electronic address: p.barboni@studiodazeglio.it.

Chiara La Morgia (C)

Department of ophthalmology, IRCCS Istituto delle Scienze Neurologiche di Bologna, (C.L.M., L.C., V.C.) Bologna, Italy.

Maria Lucia Cascavilla (ML)

From the Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan (P.B., M.L.C., M.B., V.S., F.B.).

Eun Hee Hong (EH)

Moorfields Eye Hospital, London, United Kingdom (E.H.H., A.M., N.J., P.Y-W-M.); Department of Ophthalmology, Hanyang University College of Medicine, Seoul, Korea (E.H.H.).

Marco Battista (M)

From the Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan (P.B., M.L.C., M.B., V.S., F.B.).

Anna Majander (A)

Moorfields Eye Hospital, London, United Kingdom (E.H.H., A.M., N.J., P.Y-W-M.); UCL Institute of Ophthalmology, University College London, London, United Kingdom (A.M., N.J., P.Y-W-M.); Department of Ophthalmology, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland (A.M.).

Leonardo Caporali (L)

Department of ophthalmology, IRCCS Istituto delle Scienze Neurologiche di Bologna, (C.L.M., L.C., V.C.) Bologna, Italy.

Vincenzo Starace (V)

From the Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan (P.B., M.L.C., M.B., V.S., F.B.).

Giulia Amore (G)

Unit of Neurology, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna (G.A., M.C., V.C.).

Antonio Di Renzo (AD)

IRCCS G.B. Bietti Foundation I.R.C.C.S., Rome (A.D.R., V.P.).

Michele Carbonelli (M)

Department of ophthalmology, Studio Oculistico d'Azeglio (P.B., M.C.); Unit of Neurology, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna (G.A., M.C., V.C.).

Paolo Nucci (P)

Department of Clinical Science and Community Health, University of Milan, Milan, (P.N.), Italy.

Neringa Jurkute (N)

Moorfields Eye Hospital, London, United Kingdom (E.H.H., A.M., N.J., P.Y-W-M.); UCL Institute of Ophthalmology, University College London, London, United Kingdom (A.M., N.J., P.Y-W-M.).

Benson S Chen (BS)

Cambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge (B.S.C., P.Y-W-M.); Cambridge Eye Unit, Addenbrooke's Hospital, Cambridge University Hospitals, (B.S.C., P.Y-W-M.), Cambridge, United Kingdom.

Roberta Panebianco (R)

Department of Ophthalmology, University of Catania, Catania (R.P.).

Anna Maria De Negri (AM)

Azienda Ospedaliera San Camillo-Forlanini (A.M.D.N).

Federico Sadun (F)

Ospedale Oftalmico Roma, Rome, (F.S.), Italy.

Vincenzo Parisi (V)

IRCCS G.B. Bietti Foundation I.R.C.C.S., Rome (A.D.R., V.P.).

Francesco Bandello (F)

From the Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan (P.B., M.L.C., M.B., V.S., F.B.).

Alfredo A Sadun (AA)

and Doheny Eye Institute/UCLA School of Medicine, Los Angeles, California, USA (A.A.S).

Valerio Carelli (V)

Department of ophthalmology, IRCCS Istituto delle Scienze Neurologiche di Bologna, (C.L.M., L.C., V.C.) Bologna, Italy; Unit of Neurology, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna (G.A., M.C., V.C.).

Patrick Yu-Wai-Man (P)

Moorfields Eye Hospital, London, United Kingdom (E.H.H., A.M., N.J., P.Y-W-M.); UCL Institute of Ophthalmology, University College London, London, United Kingdom (A.M., N.J., P.Y-W-M.); Cambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge (B.S.C., P.Y-W-M.); Cambridge Eye Unit, Addenbrooke's Hospital, Cambridge University Hospitals, (B.S.C., P.Y-W-M.), Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH